openPR Logo
Press release

Thrombosis Drugs Market Set To Grow According To Forecasts Due To Increasing Prevalence Of Obesity Forecast, 2018 - 2026

01-21-2020 01:22 PM CET | Health & Medicine

Press release from: TMR

Thrombosis Drugs Market

Thrombosis Drugs Market

Transparency Market Research (TMR) titled “Thrombosis Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the new report, the global thrombosis drugs market was valued at approximately US$ 20,012 Mn in 2017. It is projected to expand at a CAGR of more than 9.5% from 2018 to 2026.

The report suggests that the rise in geriatric population, which is more susceptible to thrombosis events, globally, is likely to boost the demand for thrombosis drugs during the forecast period. North America and Europe are likely to dominate the global thrombosis drugs market due to increase in awareness and rise in focus of key players on the development of new drugs in the market in these regions. Increasing penetration and rising prevalence of thrombosis events in emerging markets such as Japan, Hong Kong, and Taiwan are likely to boost the thrombosis drugs market in Asia Pacific at a CAGR of 9.0% from 2018 to 2026.

thrombosis-drugs-market.jpg

Expansion of the Generic Drugs Industry to Hamper the Market

The generic drugs industry has witnessed significant expansion in the last few years. Branded drugs of molecule such as heparin consistently lose market share due to the availability and continuous launch of generic version of the drugs. For example, recently, in January 2018, Aurobindo Pharma launched fondaparinux sodium injection, a generic version of Arixtra brand, which is utilized to prevent deep vein thrombosis, after its patent expired.

For More Details, Request A PDF Brochure Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=46293

Low Molecular Weight Heparin to Lose Market Share

The report offers detailed segmentation of global thrombosis drugs market based on drug class, indication, and distribution channel. Based on drug class, the factor Xa inhibitor drugs segment is estimated to account for a large share of the global market by the end of the forecast period. This is due to the increase in utilization of factor Xa inhibitor drugs for their advantages such as no drug monitoring is required after intake. Moreover, several studies have proved that factor Xa inhibitor drugs are effective in both deep vein thrombosis and pulmonary embolism and help reduce the rate of hospitalization after usage. The low molecular weight heparin segment is anticipated to lose market share during the forecast period, and is expected to decline from 14.7% held in 2017 to reach 5.9% by 2026. Patent expiry, availability of generic drugs, and increased preference toward oral formulation of drugs from injectable dose are factors that are likely to hamper this segment.

Pulmonary Embolism: Top Indication of Thrombosis Drugs

In terms of indication, the pulmonary embolism segment is projected to hold for a dominant share of the global thrombosis drugs market by the end of the forecast period. The segment is likely to expand at a CAGR more than 10.0% from 2018 to 2026. Most companies are focused on developing low-cost drugs to serve the large pulmonary embolism patients pool across the globe; therefore, the pulmonary embolism segment is likely to account for a dominant share of the market. For example, the U.K-based pharmaceutical company, AstraZeneca, is developing a drug candidate called Brilliant Thales for the indication of cardiovascular events. The atrial fibrillation segment accounted for more than 27.0% share of the global thrombosis drugs market, in terms of value, in 2017. It is anticipated to expand at a substantial pace during the forecast period. The segment is likely to gain market share marginally to reach 27.8% by 2026.

The Market in North America to Expand at a Considerable Pace and Create Incremental Opportunity

In terms of value, North America held a major share of the global market in 2017. This is due to the high health care expenditure and rise in awareness about the advantages of new oral anticoagulant drugs formulation in the U.S. Furthermore, several players such as Johnson & Johnson and Exithera Pharmaceutical have increased investment in research & development to develop advanced drugs to treat thrombosis. Thus, the presence of these players is projected to propel the thrombosis drugs market in North America at a rapid pace during the forecast period. Increase in incidence of age-related chronic conditions such as cancer and neurological illnesses increases thrombosis events in Asia Pacific. Moreover, improving economic conditions, rise in spending power, and better access to health care service fuels the market in Asia Pacific. Economic growth in countries such as Brazil is increasing research & development activities and expenditure on treatment in Latin America. These factors are likely to propel the thrombosis drugs market in Latin America. It is expected to expand at a CAGR of 9.0% from 2018 to 2026.

Bayer AG, Aspen Pharmacare Holdings Limited, and Boehringer Ingelheim GmbH to Dominate the Market

The report also provides profiles of leading players operating in the global thrombosis drugs market. These include GlaxoSmithKline plc, Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, and Pfizer, Inc. Expansion of product portfolio through developing new products or by acquisition and licensing agreement to develop products is a key strategy adopted by several key players. For instance, in 2015, Isis Pharmaceuticals, Inc., entered into an exclusive license agreement with Bayer HealthCare to develop and commercialize ISIS-FXIRx for the prevention of thrombosis. Other key players are also adopting such strategies.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Thrombosis Drugs Market Set To Grow According To Forecasts Due To Increasing Prevalence Of Obesity Forecast, 2018 - 2026 here

News-ID: 1902789 • Views: 71

More Releases from TMR

02-11-2020 | Health & Medicine
TMR
Bone Growth Stimulators Market Is Likely To Tread Along A Healthy Growth Track O …
Bone Growth Stimulators Market: Introduction According to the report, the global bone growth stimulators market was valued at US$ 1.3 Bn in 2018 and is projected to expand at a CAGR of ~5% from 2019 to 2027. Bone growth stimulation is a therapy used to aid bone healing process after a fracture or spinal fusion surgery. Rise in geriatric population globally, increase in prevalence of orthopedic diseases and rising inclination of
02-11-2020 | Health & Medicine
TMR
HIV Self-test Kits Market Report Examines Growth Overview And Predictions On Siz …
HIV Self-test Kits Market: Introduction According to the report, the global HIV self-test kits market was valued at US$ 60.3 Mn in 2018 and is projected to expand at a CAGR of ~17% from 2019 to 2027. HIV self-testing is a screening test, which detects the presence of HIV-1/2 antibodies. HIV self-testing is a test in which a person collects his/her own specimen and performs an HIV test in a private
02-11-2020 | Health & Medicine
TMR
Fetal Monitoring Systems Market Size Examines Growth Overview And Predictions On …
Fetal Monitoring Systems Market: Introduction Transparency Market Research has published a new report titled "Fetal Monitoring Systems Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027". According to the report, the global fetal monitoring systems market was valued at approximately US$ 2.8 Bn in 2018. It is expected to expand at a CAGR of ~3% during the forecast period from 2019 to 2027. Monitoring procedures are the basis
02-11-2020 | Health & Medicine
TMR
Orthopedic Biomaterials Market Size Is In Tremendous Growth Phase | Analysis Rep …
Orthopedic Biomaterials Market: Introduction According to the report, the global orthopedic biomaterials market was valued at US$ 11.3 Bn in 2018 and is projected to expand at a CAGR of ~7% from 2019 to 2027. Rise in percentage of population requiring orthopedic implants, and increase in incidence rate of injuries related to accidents, sports, and adventure are anticipated to augment the global orthopedic biomaterials market from 2019 to 2027. North America

All 5 Releases


More Releases for Drugs

Global Cardiovascular Drugs Market
Global Cardiovascular Drugs Market – Industry Analysis and Forecast (2018-2026) – by Drug Class, Indications, Distribution Channels, and Region. Global Cardiovascular Drugs Market was valued at US$ 80.5 Bn in 2017 and is expected to reach US$ 98.8 Bn by 2026, at a CAGR of 2.6 % during the forecast period. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data,
Cardiovascular Drugs Market | Insights
Some of the common cardiovascular diseases include hypertensive heart disease, rheumatic heart disease, ischemic heart disease, inflammatory heart disease, and cerebrovascular heart disease. Major problems associated with hypertensive heart disease include angina, hypertrophy, and heart failure. These problems are caused due to high blood pressure in the heart’s arteries and muscles, which causes narrowing of arteries and thickening and enlargement of heart. The global cardiovascular drug market is primarily driven
Immunotherapy Drugs Market
Immunotherapy drugs are used to treat cancer, infection, respiratory and autoimmune disorders. Immunotherapies either stimulate the activities done by specific components of the immune system or counteract the signals that are produced by the cancer cells and suppress the immune responses. The Immunotherapy Drugs Market accounted to USD 107 billion in 2016 growing at a CAGR of 13.2% during the forecast period of 2017 to 2024. The upcoming market report contains
Immunotherapy Drugs Market
Immunotherapy is the management of a disease by enhancing, suppressing, or inducing an immune response. Some immunotherapies are designed to magnify or elicit an immune response. They are known as activation immunotherapies. However, some immunotherapies that suppress or reduce the immune response are known as suppression immunotherapies. Cell-based immunotherapies are useful for some types of cancers. Immune effector cells includingmacrophages, dendritic cells, lymphocytes, cytotoxic T lymphocytes (CTL), natural killer cells
Tardive Dyskinesia Drugs Market
Tardive dyskinesia (TD) is a form of dyskinesia that is difficult to treat. It is a nerve disorder characterized by involuntary movements such as jaw, lips, and tongue, considered as grimacing, sticking the tongue out, and lip smacking. Some other symptoms are an individual experiencing involuntary movement of the lower and upper extremities and also breathing choking. According to Center for Drug Evaluation and Research, tardive dyskinesia can lead to
Erythropoietin Drugs Market
Erythropoietin alfa is widely used to treat anemia and increase the red blood cells count in the body. Erythropoietin drugs are developed in vitro by extracting the erythropoietin from the human body and developing it through the use of recombinant DNA technology. Erythropoietin drugs are also used to treat anemia induced from cancer, multiple myloma and HIV associated anemia. Recombinant DNA technology has allowed researchers to develop synthetic forms of